Home HEALTH Big Winners: Aastrom Biosciences Inc (NASDAQ:ASTM), Hansen Medical, Inc.(NASDAQ:HNSN), Dendreon Corporation(NASDAQ:DNDN)

Big Winners: Aastrom Biosciences Inc (NASDAQ:ASTM), Hansen Medical, Inc.(NASDAQ:HNSN), Dendreon Corporation(NASDAQ:DNDN)

0
0

Aastrom Biosciences Inc (NASDAQ:ASTM) shares soared 31.15% to $0.774 on no official news. On May 20, 2013, Aastrom Biosciences received a notification letter from Nasdaq’s Listing Qualifications Department (“Nasdaq”) advising the Company that for the past 30 consecutive business days, the Company did not meet the $35 million minimum Market Value of Listed Securities (“MVLS”) for its common stock set forth in Nasdaq Listing Rule 5550(b)(2) (the “MVLS rule”).

Hansen Medical, Inc.(NASDAQ:HNSN) shares climbed 22.22%  to $1.87. The company, on August 5, announced that the first patients have been successfully enrolled in the new study design of its ARTISAN-AF Trial, a pivotal clinical trial evaluating the use of Hansen Medical’s Artisan(R) family of Control Catheters with its Sensei(R) X Robotic Catheter System for treatment of Atrial Fibrillation (AF), the most common cardiac arrhythmia. In May, the Company announced that it had received conditional approval of the new study design from the U.S. Food and Drug Administration (FDA).

Dendreon Corporation(NASDAQ:DNDN) shares increased 13.70% to $5.23. The company announced that management will host a conference call on Thursday, August 8, 2013, at 4:30 p.m. EDT to review second quarter financial results.

Additionally, the company on July 17 announced the receipt of approval by the European Medicines Agency for Medicinal Products for Human Use which had granted the use of PROVENGE to be used for the treatment of patients suffering from minimally Symptomatic or Asymptomatic Metastatic castrate resistant prostate cancer in European Union. This recommendation of the product by CHMP had further been followed by another positive recommendation made by Committee for Advanced Therapy.

gment-�F <bȯ����/html> �I nnȯ����are for the quarter, beating the analysts’ consensus estimate of $0.25 by $0.03.